Thromboembolic complications in children with cancer

Thrombosis Research

Volumn 118, Issue 1, 2006, Pages 137-152

  Wiernikowski, John T ^a   Athale, Uma H ^a,b  

^a MCMASTER CHILDREN S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulant therapy; Cancer in children; Chemotherapy; Thromboembolism

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ARGATROBAN; ASPARAGINASE; BLOOD CLOTTING FACTOR 5 LEIDEN; CORTICOSTEROID; COUMARIN; DALTEPARIN; DANAPAROID; ENOXAPARIN; FLUOROURACIL; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PLATINUM; PROTAMINE SULFATE; PROTHROMBIN; REVIPARIN; STEROID; THALIDOMIDE; THROMBIN; THROMBIN INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; UROKINASE; WARFARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANATOMY; ANOREXIA; ANTICOAGULATION; BLEEDING; BLOOD VESSEL INJURY; BONE MINERAL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CENTRAL VENOUS CATHETER; CHILDHOOD CANCER; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SUBSTITUTION; FEBRILE NEUTROPENIA; FOOD DRUG INTERACTION; GENE MUTATION; GENETIC POLYMORPHISM; GROUPS BY AGE; HEART RIGHT ATRIUM; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HEREDITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTRACARDIAC THROMBOSIS; INVASIVE PROCEDURE; LUNG EMBOLISM; MOLECULAR DYNAMICS; MUCOSA INFLAMMATION; NAUSEA; OCCLUSIVE CEREBROVASCULAR DISEASE; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PATIENT MONITORING; PEDIATRICS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEPSIS; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS; CHILD; INFANT; NEOPLASM; PRESCHOOL CHILD; RISK FACTOR;

ANTICOAGULANTS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; NEOPLASMS; RISK FACTORS; THROMBOEMBOLISM; THROMBOSIS;

EID: 33747593734     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.06.004     Document Type: Review

References (147)

1. Bick R.L. Cancer-associated thrombosis. N Engl J Med 349 (2003) 109-111
2. Lee A.Y.Y., and Levine M.N. Venous thromboembolism and cancer: risks and outcome. Circulation 107 (2003) I-17-I-21
3. Levine M, Lee AY, Kakkar AK. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer.
4. Sutherland D.E., Weitz I.C., and Liebman H.A. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 72 (2003) 43-52
5. Sallah S., Wan J.Y., and Nguyen N.P. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 87 (2002) 575-579
6. Kuhle S., Male C., and Mitchell L. Developmental hemostasis: pro- and anticoagulant systems during childhood. Semin Thromb Hemost 29 (2003) 329-337
7. Andrew M., Vegh P., Johnston M., Bowker J., Ofosu F., and Mitchell L. Maturation of the hemostatic system during childhood. Blood 80 (1992) 1998-2005
8. Nowak-Gottl U., Kosch A., and Schlegel N. Thromboembolism in newborns, infants, and children. Thromb Haemost 86 (2001) 464-474
9. Monagle P., Michelson A.D., Bovil E., and Andrew M. Antithrombotic therapy in children. Chest 119 (2001) 344S-370S
10. van Ommen C.H., Heijboer H., Baller H.R., Hirasing R.A., Heijmanom H.S.A., and Peter M. Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands. J Pediatr 139 (2001) 676-681
11. Andrew M., David M., Adams M., Ali K., Anderson R., Barnard D., et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 83 (1994) 1251-1257
12. Streif W., and Adrew M.E. Venous thromboembolic events in pediatric patients. Diagnosis and management. Hematol Oncol Clin North Am 12 (1998) 1283-1312
13. Schmidt B., and Andrew M. Neonatal thrombosis: report of a Canadian and International Registry. Pediatrics 96 (1995) 939-943
14. Athale U.H., and Chan A.K.C. Thrombosis in children with acute lymphoblastic leukemia: Part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 111 (2003) 125-131
15. Wermes C., Prondzinski M.vD., Lichtinghagen R., Barthels M., Welte K., and Sykora K.W. Clinical relevance of genetic risk factors for thrombosis in pediatric oncology patients with central venous catheters. Eur J Pediatr 158 Suppl 3 (1999) S143-S146
16. Monagle P., Adams M., Mahoney M., Ali K., Barnard D., Bernstein M., et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 47 (2000) 763-766
17. Massicotte M.P., Dix D., Monagle P., Adams M., and Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of venous thromboembolic complications. J Pediatr 133 (1998) 770-776
18. Silverman L.B., Gelber R.D., Dalton V.K., Asselin B.L., Barr R.D., Clavell L.A., et al. Improved outcome of children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01. Blood 97 (2001) 1211-1217
19. Athale U.H., Mah D., Davidson A., Nagel K., Odame I., and Chan A.K.C. Thromboembolism (TE) in children with acute lymphoblastic leukemia (ALL) treated on Dana Farber Cancer Institution (DFCI) protocols: effect of age and risk stratification of ALL. Med Pediatr Oncol 41 (2003) 310
20. Sifontes M.T., Nuss R., Hunger S.P., Wilimas J., Jacobson L.J., and Manco-Johnson M.J. The factor V Leiden mutation in children with cancer and thrombosis. Br J Haematol 96 (1997) 484-489
21. Smith M.A., and Gloeckler Ries L.A. Childhood cancer: incidence, survival, and mortality. In: Pizzo P.A., and Poplack D.G. (Eds). Principles and practice of pediatric oncology. 4th edition (2002), Lippincott Williams & Wilkins, Philadelphia 1-20
22. Tabori U., Beni-Adani L., Dvir R., Burstein Y., Feldman Z., Pessach I., et al. Risk of venous thromboembolism in pediatric patients with brain tumors. Pediatr Blood Cancer 43 (2004) 633-636
23. Deitcher S.R., Gajjar A., Kun L., and Heideman R.L. Clinically evident venous thromboembolic events in children with brain tumors. J Pediatr 145 (2004) 848-850
24. Glacer D.W., Medeiros D., Rollins N., and Buchanan G.R. Catheter-related thrombosis in children with cancer. J Pediatr 138 (2001) 255-259
25. Reddingius R.E., Patte C., Couanet D., Kalifa C., and Lemerle J. Dural sinus thrombosis in children with cancer. Med Pediatr Oncol 29 (1997) 296-302
26. Packer R.J., Rorke L.B., Lange B.J., Siegel K.R., and Evans A.E. Cerebrovascular accidents in children with cancer. Pediatrics 76 (1985) 194-201
27. Mitchell L.G., Sutor A.N., and Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost 21 (1995) 390-401
28. Mitchell L.G., Andrew M., Hanna K., Abshire T., Anderson R., Cherrick I., et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with l-asparaginase. Results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer 97 (2003) 508-516
29. Freytes C.O. Thromboembolic complications related to indwelling central venous catheters in children. Curr Opin Oncol 15 (2003) 289-292
30. Bona R. Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Hemost 25 (1999) 147-153
31. Monreal M., Alastrue A., Rull M., Mira X., Muxart J., Rosell R., et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75 (1996) 251-253
32. McGee D.C., and Gould M.K. Preventing complications of central venous catheterization. N Engl J Med 348 (2003) 1123-1133
33. Barnes C., Newall F., and Monagle P. Post thrombotic syndrome. Arch Dis Child 86 (2002) 212-214
34. Balestreri L., De Cicco M., Matovic M., Coran F., and Morassut S. Central venous catheter related thrombosis in clinically asymptomatic oncologic patients; a phlebographic study. Eur J Radiol 20 (1995) 108-111
35. Schwarz R.E., Groeger J.S., and Coit D.G. Subcutaneously implanted central venous access devices in cancer patients. Cancer 79 (1997) 1635-1640
36. Kock H.J., Pietsch M., Krause U., Wilke H., and Eigler F.W. Implantable vascular access systems: experience in 1500 patients with totally implanted central venous port systems. World J Surg 22 (1998) 12-16
37. Chemaly R.F., Barbera de Parres J.B., Rehm S.J., Adal K.A., Lisgaris M.V., Katz-Scott D.S., et al. Venous thrombosis associated with peripherally inserted central catheters: a retrospective analysis of the Cleveland Clinic experience. Clin Infect Dis 34 (2002 May 1) 1179-1183
38. Koolen D.A., van Laarhoven H.W., Wobbes T., and Punt C.J. Single center experience with tunneled central venous catheters in 150 cancer patients. Neth J Med 60 (2002) 397-401
39. Molinari A.C., Castagnola E., Mazzola C., Piacentino M., and Fratino G. Thromboembolic complications related to indwelling central venous catheters in children with oncological/ haematological diseases: a retrospective study of 362 catheters. Support Care Cancer 9 (2001) 539-544
40. Male C., Chait P., Ginsberg J.S., Hanna K., Andrew M., Halton J., et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep venous thrombosis in the upper body in children. Thromb Haemost 87 (2002) 593-598
41. Male C., et al., for the PARKAA investigators. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood 101 (2003) 4273-4278
42. Knoffler R., Siegert E., Lauterbach I., Taut-Sack H., Siegert G., Gehrisch S., et al. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy: impact of central venous lines. Eur J Pediatr 185 (1999) S147-S150
43. Mathew L.G., Ortin M., and Pinkerton C.R. Thrombotic complications in children treated for ALL: a single center experience. Med Pediatr Oncol 41 (2003) 310
44. Rudd E., Holmstrom H., Natvig S., and Wesenberg F. Prevalence of thrombophilia and central venous catheter-associated neck vein thrombosis in 41 children with cancer - a prospective study. Med Pediatr Oncol 38 (2002) 405-410
45. Barnes C., Newall F., and Monagle P. Thromboembolic complications related to indwelling central venous catheters in children with oncological/hematological diseases: a retrospective study of 362 catheters. Support Care Cancer 10 (2002) 256-257
46. McLean T.W., Fisher C.J., Snively B.M., and Chauvenet A.R. Central venous lines in children with lesser risk acute lymphoblastic leukemia: optimal type and timing of placement. J Clin Oncol 23 (2005) 3024-3029
47. Hausler M., Hubner D., Delhaas T., and Muhler E.G. Long term complications of inferior vena cava thrombosis. Arch Dis Child 85 (2001) 228-233
48. Andrew M., Marzinotto V., Pencharz P., Zlotkin S., Burrows P., Ingram J., et al. A cross sectional study of catheter-related thrombosis in children receiving total parenteral nutrition at home. J Pediatr 126 (1995) 358-363
49. Marzinoote V., Choi M., Massicotte M.P., and Chan A.K.C. Post-thrombotic syndrome in children with deep vein thrombosis. Thromb Haemost (2001) OC962 [suppl]
50. Raizer J.J., and DeAngelis L.M. Cerebral sinus thrombosis diagnosed by MRI and MR venography in cancer patients. Neurology 54 (2000) 1222-1226
51. Legrand I., Lalande G., Neuenschwander S., Dulac O., and Kalifa L.G. Thrombosis du sinus longitudinal superior au cours du treatment de lymphoma hez l'enfant. J Radiol 67 (1986) 595-600
52. Korones D.N., Buzzard C.J., Asselin B., and Harris J.P. Right atrial thrombi in children with cancer and indwelling catheters. J Pediatr 128 (1996) 841-846
53. Joffe H.V., and Goldhaber S.Z. Upper-extremity deep vein thrombosis. Circulation 106 (2002) 1874-1880
54. Rickles F.R., and Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 102 (2001) V215-V224
55. Goldenberg N., Kahn S.R., and Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol 21 (2003) 4194-4199
56. Nowak-Gottl U., Munchow N., Klippel U., Paulussen M., Bielack S., and Ulrich K. The course of fibrinolytic proteins in children with malignant bone tumors. Eur J Pediatr 158 (1999) S151-S153
57. Chidi C.C., King D.R., and Bales Jr. E.T. An ultrastructural study of the intimal injury by an indwelling umbilical catheter. J Pediatr Surg 18 (1983) 109
58. Wakefield A., Cohen Z., Rosenthal A., Craig M., Jeejeebhoy K.N., Gotlieb A., et al. Thrombogenicity of total parenteral nutrition solutions: II. Effect on induction of endothelial cell procoagulant activity. Gastroenterology 97 (1989) 1220-1228
59. Pottecher T., Forrler M., Picardat P., Krause D., Bellocq J.P., and Otteni J.C. Thrombogenicity of central venous catheters: prospective study of polyethylene, silicone and polyurethane catheters with phlebography or post mortem examination. Eur J Anaesthesiol 1 (1984) 361-365
60. Koksoy C., Kuzu A., Kutlay J., Erden I., Ozcan H., and Ergin K. The diagnostic value of color Doppler ultrasound in central venous catheter related thrombosis. Clin Radiol 50 (1995) 687-699
61. Gould J.R., Carloss H.W., and Skinner W.L. Groshong catheter associated subclavian venous thrombosis. Am J Med 95 (1993) 419-423
62. Craft P.S., May J., Dorigo A., Hoy C., and Plant A. Hickman catheters: left-sided insertion, male gender, and obesity are associated with an increased risk of complications. Aust N Z J Med 26 (1996) 33-39
63. De Cicco M., Matovic M., Balestreri L., Panarello G., Fantin D., Morassut S., et al. Central venous thrombosis: an early and frequent complication of cancer in patients bearing long term silastic catheters - a prospective study. Thromb Res 86 (1997) 101-113
64. Couban S., Petrella M.P., Egan B., et al. Risk factors for central venous catheter associated thrombosis in patients with cancer. Blood 98 (2001) 267 [abstract]
65. Cimochowski G.E., Worley E., Rutherford W.E., Sartain J., Blondin J., and Harter H. Superiority of the internal jugular over the subclavian access for temporary dialysis. Nephron 54 (1990) 154-161
66. Schillinger F., Schillinger D., Montagnac R., and Milcent T. Post catheterization vein stenosis in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. Nephrol Dial Transplant 6 (1991) 722-724
67. Henriques III H.F., Karmy-Jones R., Knoll S.M., Copes W.M., and Giaordano J.M. Avoiding complications of long term venous access. Am Surg 59 (1993) 555-558
68. Beck C., Dubois J., Grignon A., Lacroix J., and David M. Incidence and risk factors of catheter related deep vein thrombosis in a pediatric intensive care unit: a prospective study. J Pediatr 133 (1998) 237-241
69. Trerotola S.O., Kuhn-Fulton J., Johnson M.S., Shah H., Ambrosius W.T., and Kneebone P.H. Tunneled infusion catheters: increased incidence of symptomatic venous thrombosis after subclavian vs. internal jugular access. Radiology 217 (2000) 89-93
70. Mirro Jr. J., Rao B.N., Kumar M., Rafferty M., Hancock M., Austin B.A., et al. A comparison of placement techniques and complications of externalized catheters and implantable port use in children with cancer. J Pediatr Surg 25 (1990) 120-124
71. Athale U.H., and Chan A.K.C. Thrombosis in children with acute lymphoblastic leukemia: Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 111 (2003) 199-212
72. Lee A.Y.Y., and Levine M.N. The thrombophiliac state induced by therapeutic agents in the cancer patients. Semin Thromb Hemost 25 (1999) 137-145
73. Nowak-Gottl U., Heinecke A., von Kries R., Nurnberger W., Munchow N., and Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia. Impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 103 (2001) 165-172
74. Marx G.M., Steer C.B., Harper P., Pavlakis N., Rixe O., and Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!. J Clin Oncol 20 (2002) 1446-1448
75. Zangari M., Anaissie E., Barlogie B., Badros A., Desikan R., Gopal V.A., et al. Increased risk of deep vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 (2001) 1614-1615
76. Osman K., Comenzo R., and Rajkumar S.V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344 (2001) 1951-1952
77. Urbauer E., Kaufmann H., Nosslinger T., Raderer M., and Drach J. Thromboembolic events during treatment with thalidomide. Blood 99 (2002) 4247-4248
78. Kuenen B.C., Rosen L., and Smit E.F. Dose finding and pharmacokinetic study of cisplatin, gemcitabine and SU5416 in patients with solid tumors. J Clin Oncol 20 (2002) 1657-1667
79. Cropp G.F., and Hannah A.L. SU5416, a molecularly targeted novel anti-angiogenic drug: clinical pharmacokinetics and safety review. Clin Cancer Res 6 (2002) 95
80. Hack C.E. Tissue factor pathway of coagulation in sepsis. Crit Care Med 28 (2000) S25-S30
81. Esmon C. The protein C pathway. Crit Care Med 28 (2000) S44-S48
82. Tait R.C., Walker I.D., Perry D.J., Islam S.I., Daly M.E., McCall F., et al. Prevalence of antithrombin deficiency in healthy population. Br J Haematol 87 (1994) 106-112
83. Koster T., Rosendaal F.R., Briet E., van der Meer F.J., Colly L.P., Trienekens P.H., et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden thrombophilia study). Blood 85 (1995) 2756-2761
84. Monagle P., Andrew M., Halton J., Marlar R., Jardine L., Vegh P., et al. Homozygous protein C deficiency: description of a new mutation and successful treatment with low molecular weight heparin. Thromb Haemost 79 (1998) 756-761
85. Dahlback B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 85 (1995) 607-614
86. Price D.T., and Ridker P.M. Factor V Leiden mutation and the risks of thromboembolic disease: a clinical perspective. Ann Intern Med 127 (1997) 895-903
87. De Stefano V., Leone G., Mastrangelo S., Tripodi A., Rodeghiero F., Castaman G., et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Hemost 72 (1994) 352-358
88. Lane D.A., Mannucci P.M., Bauer K.A., Bertina R.M., Bochkov N.P., Boulyjenkov V., et al. Inherited thrombophilia: Part I. Thromb Haemost 76 (1996) 651-662
89. Lane D.A., Mannucci P.M., Bauer K.A., Bertina R.M., Bochkov N.P., Boulyjenkov V., et al. Inherited thrombophilia : part II. Thromb Hemost 76 (1996) 824-834
90. Ridker P.M., Hennekens C.H., and Miletich J.P. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 99 (1999) 999-1004
91. Crowther M.A., and Kelton J.G. Congenital thrombophiliac states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 138 (2003) 128-134
92. Nowak-Gottl U., Koch H.G., Aschka I., Kohlase B., Vielhaber H., Kurleman G., et al. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol 92 (1996) 992
93. Nowak-Gottl U., Dubbers A., Kececioglu D., Koch H.G., Kothoff S., Runde J., et al. Factor V Leiden, protein C, lipoprotein (a) in catheter related thrombosis in childhood: a prospective study. J Pediatr 131 (1997) 608-612
94. Bonduel M., Sciuccati G., Hepner M., Pieroni G., Torres A.F., Mardaraz C., et al. Factor V Leiden and prothrombin gene G20210A mutation in children with cerebral thromboembolism. Am J Hematol 73 (2003) 81-86
95. Wiemels J.L., Smith R.N., Taylor G.M., Eden O.B., Alexander F.E., and Greaves M.F. Methylene tetrahydrofolate reductase (MTHFR) polymorphism and risks of molecularly defined subtypes of childhood leukemia. PNAS 98 (2001) 4004-4009
96. Athale U.H., and Chan A.K.C. Thrombosis in children with acute lymphoblastic leukemia: Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment. Thromb Res 111 (2003) 321-327
97. Nowak-Gottl U., Wermes C., Junker R., Koch H.G., Schobess R., Fleischhack G., et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 93 (1999) 1595-1599
98. Elhasid R., Lanir N., Sharon R., Arush M., Weyl B., Levin C., et al. Prophylactic therapy with enoxaparin during l-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 12 (2001) 367-370
99. Mauz-Korholz C., Junker R., Gobel U., and Nowalk-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and 97 protocols). Thromb Haemost 83 (2000) 840-843
100. Kishi S., Griener J., Cheng C., Das S., Cook E.H., Pei D., et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 21 (2003) 3084-3091
101. Hutten B.A., Prins M.H., Gent M., Ginsberg J., Tijssen J.A.P., and Buller H.R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18 (2000) [3078-0383]
102. Prandoni P., Lensing A.W.A., Piccioli A., and Bernardi E. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 (2002) 3484-3488
103. Randolph A.G., Cook D.J., Gonzales C.A., and Andrew M. Benefit of heparin in central venous and pulmonary catheters. A meta analysis of randomized controlled trials. Chest 113 (1998) 165-171
104. Choi M., Massicotte P., Marzinotto V., Chan A.K., Holmes J.L., and Andrew M. The use of alteplase to restore patency of central venous lines in pediatric patients: a cohort study. J Pediatr 139 (2001) 152-156
105. Wiernikowski J.T., Crowther M., Clase C.M., Ingram A., Maureen A., and Chan A.K.C. Stability and sterility of recombinant tissue plasminogen activator at - 30 °C. Lancet 355 (2000) 2221
106. Bern M.M., Lokich J.J., Wallach S.R., Bothe Jr. A., Benotti P.N., Arkin C.F., et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112 (1990) 423-428
107. Reichart P., Kretzschmar A., Biakhov M., and Irwin D. A phase III double blind placebo controlled study evaluating the efficacy and safety of daily low molecular weight heparin (dalteparin sodium, fragmin) in preventing catheter related complications in cancer patients with central venous catheters. Clin Oncol 21 (2002) 1474 [abstract]
108. Couban S., Goodyear M., Burnell M., and Dolan S. A randomized double blind placebo controlled study of low dose warfarin for the prevention of symptomatic central venous catheter associated thrombosis in patients with cancer. Blood 100 (2002) 2769 [abstract]
109. Massicotte P., Julian J.A., Marzinotto V., Gent M., Shields K., Chan A.K., et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 109 (2003) 93-99
110. Massicotte P., Julian J.A., Gent M., Shields K., Marzinotto V., Szechtman B., et al. An open label randomized controlled trial of low molecular weight heparin for the prevention of central venous line related thrombotic complications in children: the PROTEKT trial. Thromb Res 109 (2003) 101-108
111. Mitchell L., Andrew M., Hanna K., Abshire T., Halton J., Wu J., et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PARKAA study. Thromb Haemost 90 (2003) 235-244
112. Streif W., Mitchell L.G., and Andrew M. Antithrombotic therapy in children. Curr Opin Pediatr 11 (1999) 56-64
113. Andrew M., Marzinotto V., Massicotte P., Blanchette V., Ginsberg J., Brill-Edwards P., et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 35 (1994) 78-83
114. Potter C., Gill J.C., Scott J.P., and McFarland J.G. Heparin induced thrombocytopenia in a child. J Pediatr 121 (1992) 135-138
115. Klement D., Rammos S., Kries R., Kirschke W., Kniemeyer H.W., and Greinacher A. Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in pediatric patients even with normal platelet counts. Eur J Pediatr 155 (1996) 11-14
116. Murdoch I.A., Beattie R.M., and Silver D.M. Heparin induced thrombocytopenia in children. Acta Paediatr 82 (1993) 495-497
117. Andrew M., and de Veber G. Pediatric thromboembolism and stroke protocols (1999), B.C. Decker Inc., Hamilton
118. Severin T., and Sutor A.H. Heparin induced thrombocytopenia in pediatrics. Semin Thromb Hemost 27 (2001) 293-299
119. Magnani H.N. Heparin-induced thrombocytopenia (HIT). An overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 70 (1993) 554-561
120. Deitcher S.R., Topoulos A.P., Bartholomew J.R., and Kichus-Chrisant M.R. Lepirudin anticoagulation for heparin induced thrombocytopenia. J Pediatr 140 (2002) 264-266
121. Nguyen T.N., Gal P., Ransom J.L., and Carlos R. Lepirudin use in a neonate with heparin induced thrombocytopenia. Ann Pharmacother 37 (2003) 229-233
122. Murphy M.S., John P.R., Mayer A.D., Buckels J.A., and Kelly D.A. Heparin therapy and bone fractures. Lancet 340 (1992) 1098
123. Avioli L.V. Heparin induced osteopenia: an appraisal. Adv Exp Med Biol 52 (1975) 375-387
124. Sackler J.P., and Liu L. Heparin induced osteoporosis. Br J Radiol 45 (1973) 548-550
125. Roebuck D.J. Skeletal complications in pediatric oncology patients. Radiographics 19 (1999) 873-875
126. Halton J.M., Atkinson S.A., Fraher L., Webber C., Gill G.J., Dawson S., et al. Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia. J Bone Miner Res 11 (1996) 1774-1783
127. Arikoski P., Komulainen J., Riikonen P., Parviainen M., Jurvelin J.S., Voutilainen R., et al. Impaired development of bone mineral density during chemotherapy: a prospective analysis of 46 children newly diagnosed with cancer. J Bone Miner Res 14 (1999) 2002-2009
128. Dolovich L.R., Ginsberg J.S., Douketis J.D., Holbrook A.M., and Cheah G. A meta analysis comparing low molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type and dosing frequency. Arch Intern Med 160 (2000) 181-188
129. van Den Belt AG, Prins MH, Lensing AW, et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2: CD001100.
130. Gould M.K., Dembitzer A.D., Doyle R.L., Hastie T.J., and Garber A.M. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta analysis of randomized controlled trials. Ann Intern Med 130 (1999) 800-809
131. Levine M., Gent M., Hirsh J., Leclerc J., Anderson D., Weitz J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334 (1996) 677-681
132. Koopman M.M., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P.M., van der Meer J., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. The Tasman Study Group. N Engl J Med 334 (1996) 682-687
133. The Columbus Investigators. Low molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337 (1997) 657-662
134. Wells P.S., Kovacs M.J., Bormanis J., Forgie M.A., Goudie D., Morrow B., et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin: a comparison of patient self injection with homecare injection. Arch Intern Med 158 (1998) 1809-1812
135. Harrison L., McGinnis J., Crowther M., Ginsberg J., and Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med 158 (1998) 2001-2003
136. Lee A.Y.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low molecular weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
137. Massicotte P., Adams M., Marzinotto V., Brooker L.A., and Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 128 (1996) 313-318
138. Albisetti M., and Andrew M. Low molecular weight heparin in children. Eur J Pediatr 161 (2002) 71-77
139. Dix D., Andrew M., Marzinotto V., Charpentier K., Bridge S., Monagle P., et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 136 (2000) 439-445
140. Nohe H., Flemmer A., Rumler R., Praun M., and Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 158 Suppl 3 (1999) s134-s139
141. The REVIVE Study Group, Massicotte P., Julian J.A., Gent M., Shields K., Marzinotto V., Szechtman B., et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 109 (2003) 85-92
142. Revel-Vilk S., and Chan A.K.C. Anticoagulation therapy in children. Semin Thromb Hemost 29 (2003) 425-432
143. Hofmann S., Knoefler R., Lorenz N., Siegert G., Wendisch J., Mueller D., et al. Clinical experiences with low-molecular weight heparins in pediatric patients. Thromb Res 103 (2001) 345-353
144. Streif W., Andrew M., Marzinotto V., Massicote P., Chan A.K.C., Julian J.A., et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood 94 (1999) 3007-3014
145. Andrew M., Monagle P., and Brooker L. Oral anticoagulant therapy in pediatric patients. In: Andrew M., Monagle P.T., and Brooker L. (Eds). Thromboembolic complications during infancy and childhood (2000), BC Decker, Hamilton, Ontario 321M3-356M3
146. Buck M.L. Anticoagulation with warfarin in infants and children. Ann Pharmacother 30 (1996) 1316-1322
147. Linkins L.A., and Weitz J.I. New anticoagulants. Semin Thromb Hemost 29 (2003) 619-631